(Q41500182)

1 October 2017

1 reference

title

Cardiac effects of calcium antagonists in systemic hypertension (English)

1 reference

1 October 2017

2

F H Messerli

1 reference

1 October 2017

L Michalewicz

1

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 May 1997

1 reference

American Journal of Cardiology

1 October 2017

published in

1 reference

1 October 2017

volume

79

1 reference

1 October 2017

issue

10A

1 reference

1 October 2017

page(s)

39-46; discussion 47-8

1 reference

Differences in cardiovascular profile among calcium antagonists

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium antagonists and left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Why is nisoldipine a specific agent in ischemic left ventricular dysfunction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Factors influencing the hypotensive effects of calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Cardiovascular effects of isradipine in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Cardiovascular effects of verapamil in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of calcium entry blockers on distribution of blood volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Conduction abnormalities due to diltiazem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Use of calcium antagonists for cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Cardiovascular action of verapamil in the dog with particular reference to myocardial contractility and atrioventricular conduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium antagonists. Clinical use in the treatment of arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Unpredictable response to nifedipine in severe cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of verapamil on myocardial performance in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regional wall motion from radiopaque markers after intravenous and intracoronary injections of nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Hemodynamic effects of PN 200-110 (isradipine) in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Vascular selectivity of felodipine: clinical experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Nisoldipine CC: clinical experience in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Usefulness of echocardiographic left ventricular hypertrophy in predicting new coronary events and atherothrombotic brain infarction in patients over 62 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Prevalence and natural history of electrocardiographic left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

The effects of antihypertensive therapy on left ventricular mass in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regression of left ventricular hypertrophy with long-term treatment of nifedipine in systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Antihypertensive and cardiovascular effects of nitrendipine: a controlled study vs. placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of nicardipine on left ventricular dimensions and hemodynamics in systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of long-term treatment with sustained-release nicardipine on left ventricular hypertrophy and function in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regression of Left Ventricular Hypertrophy in the Short-Term Treatment of Hypertension With Isradipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regression of left ventricular hypertrophy with isradipine antihypertensive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Regression of left ventricular hypertrophy during long-term antihypertensive treatment--a comparison between felodipine and the combination of felodipine and metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of nitroglycerin and nifedipine on subendocardial perfusion in the presence of a flow-limiting coronary stenosis in the awake dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of diltiazem on regional coronary hemodynamics during atrial pacing in patients with stable exertional angina: implications for mechanism of action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Mechanisms of angina relief after nifedipine: a hemodynamic and myocardial metabolic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of a calcium-entry blocker (diltiazem) on regional myocardial flow and function during exercise in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Pathogenetic mechanisms of angina pectoris: expanding views

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Dynamic mechanisms in human coronary stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Angina caused by reduced vasodilator reserve of the small coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Efficacy of nifedipine therapy in patients with refractory angina pectoris: Significance of the presence of coronary vasospasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Paradoxical angina after nifedipine: angiographic documentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of intravenous and intracoronary nifedipine on coronary blood flow and myocardial oxygen consumption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Nifedipine and mortality. Grave defects in the dossier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

The risk of myocardial infarction associated with antihypertensive drug therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium antagonists and cardiovascular prognosis: a homogeneous group?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Shanghai trial of nifedipine in the elderly (STONE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Association between various drugs used for hypertension and risk of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Ventricular function and coronary hemodynamics in hypertensive heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Impaired left ventricular functional reserve in hypertensive patients with left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Asymptomatic ventricular arrhythmias and mortility risk in subjects withs with left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

ECG-gated cardiac scan and echocardiographic assessments of left ventricular hypertrophy: reversal by 6-month treatment with diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

inferred from DOI database lookup

7 January 2021

based on heuristic

The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900271-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(97)00271-3

1 reference

release_577pjh657zcibmmlxu2f5msg3y

1 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/577pjh657zcibmmlxu2f5msg3y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference